In line with tumor immunogenicity induced by itaconate, thimerosal also triggers tumor immunogenicity evidenced by significantly increased IL-2 promoter–driven LacZ activity and IFNγ production in T cells co-cultured with thimerosal-treated tumor cells (Fig. 2F,G; Appendix Fig. S2H). The gene discussed is IL2; the disease is neoplasm.